Under the terms of the agreement, MicroDose will fund the development of prototypes based upon MicroDose’s inhaler platform and incorporating Nexus6’s SmartinhalerLive technology. MicroDose will receive an option for an exclusive license to the SmartinhalerLive platform for certain fields of use.
The aim of the investigation is to demonstrate the ability to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and reporting. The SmartinhalerLive technology, providing global roaming wireless, is a natural extension of MicroDose’s electronic inhaler features and is said to facilitate better communication between the physician, patient and pharmaceutical company to improve all aspects of care.
The combined system would have benefits in both the clinical trials setting and with in-market products. By improving compliance through reminder features, and through real-time tracking of compliance, patient safety and clinical trial data management are improved. Improved control and monitoring of compliance can significantly reduce the number of patients enrolled per Phase II or Phase III clinical studies, the two companies said.
David Evans, CEO of Nexus6, said: This partnership between Nexus6 and MicroDose will enable the drug delivery marketplace to access leading edge data collection and transmission capabilities, thereby increasing pharmaceutical adherence, improving patient well-being and reducing overall healthcare costs.